Document Detail


Testosterone Therapy: Treatment of Metabolic Disturbances in Heart Failure.
MedLine Citation:
PMID:  21097668     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Heart failure (HF) is a complex progressive multisystem disease state with significant morbidity and mortality, which is not solely defined by pathology of the cardiovascular system but also is influenced by neurohormonal regulatory adjustments, peripheral cytokines, as well as hormonal and musculoskeletal dysfunction. Recent attention to the catabolic state found in patients with chronic heart failure has sparked interest in new potential targets for medical therapy. In particular, as many as 26% to 37% of men affected with HF have been found to be testosterone deficient. The severity of androgen deficiency has been shown to correlate with symptoms, functional class, and prognosis in patients with heart failure. Testosterone supplementation has been an accepted therapy in hypogonadal men with fatigue, muscle wasting, and sexual dysfunction for some time. Patients with severe HF show a similar constellation of symptoms and hypothetically would benefit from androgen replacement. Recent clinical studies have confirmed that functional, biochemical, and cardiopulmonary status in patients with HF have significant improvements when treated with testosterone supplementation. Symptomatic improvements may be obtainable in hypogonadal patients with HF who receive supplemental testosterone. This review seeks to outline the cardiovascular and peripheral effects of testosterone supplementation in patients with chronic HF.
Authors:
Jesse J Naghi; Kiran J Philip; Deanna Dilibero; Robert Willix; Ernst R Schwarz
Related Documents :
17396118 - Predictors of the response to treatment in anemic hemodialysis patients with high serum...
19491828 - Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis...
7936018 - Influence of azathioprine on the ferrokinetics of patients with renal failure before an...
1680448 - Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the trea...
23168588 - Pleuroscopy: early experience in an east malaysian state with high tuberculosis prevale...
20836308 - Incidence and patterns of lumbosacral transitional vertebrae, in patients with low back...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2010-11-19
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  -     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-11-24     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Cedars-Sinai Heart Institute, Comprehensive Transplant Program, Division of Cardiology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, US.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Rag4 glucose sensor is involved in the hypoxic induction of KlPDC1 gene expression in the yeast ...
Next Document:  Clinical Applications of Bivalirudin in the Cardiac Catheterization Laboratory.